References

  1. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: A review. Am J Hypertens 2008;21:257-264.

  2. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians clinical guideline. Ann Intern Med 2013;158:535-543.

  3. Sumorok N, Goldfarb DS. Update on cystinuria. Curr Opin Nephrol Hypertens 2013;22:427-431.

  4. Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 2013;20:165-174.

  5. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.

  6. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-838.

  7. Taylor EN, Curhan GC. Dietary calcium from 
dairy and non-dairy sources and risk of symptomatic kidney stones. J Urol 2013 Published online 
ahead of print).

  8. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-462.

  9. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. 
J Urol 1996;155:839-843.

  10. Lotan Y, Buendia Jimenez I, Lenoir-Wijnkoop I, et al. Increased water intake as a prevention strategy for recurrent urolithiasis: Major impact of compliance on cost-effectiveness. J Urol 2013;189:935-939.

  11. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999;13:679-685.

  12. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001;59:2290-2298.

  13. Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: Facts, fads, fiction, and follies. Am J Med 2011;124:896-899.

  14. Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol 2010;5:1893-1903.

  15. Wolfgram DF, Gundu V, Astor BC, Jhagroo RA. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Urolithiasis 2013; Published online ahead of print.

  16. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999;130:658-660.

  17. Asplin JR, Bauer KA, Kinder J, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003;63:662-669.

  18. Heilberg IP, Weisinger JR. Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens 2006;15:394-402.

  19. Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: Implications for patients with calcium nephrolithiasis. J Urol 2007;177:1238-1243.

  20. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999;55:234-243.

  21. Giusti A, Barone A, Pioli G, et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: A randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant 2009;24:1472-1477.

  22. Arrabal-Polo MA, Arias-Santiago S, de Haro-Munoz T, et al. Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology 2013;81:731-737.

  23. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-683.

  24. Goldfarb DS. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. Clin J Am Soc Nephrol 2011;6:2093-2097.

  25. Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res 2010;38:147-160.

  26. Arampatzis S, Ropke-Rieben B, Lippuner K, Hess B. Prevalence and densitometric characteristics of incomplete distal renal tubular acidosis in men with recurrent calcium nephrolithiasis. Urol Res 2012;40:53-59.

  27. Bergsland KJ, Coe FL, Gillen DL, Worcester EM. A test of the hypothesis that the collecting duct calcium-sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers. Am Journal Physiol Renal Physiol 2009;297:F1017-1023.

  28. Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. 
J Am Soc Nephrol 2009;20:2253-2259.

  29. Goldfarb DS. A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol 2012;7:1172-1178.

  30. Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985;134:20-23.

  31. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 2004;13:181-189.

  32. Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004;65:1422-1425.

  33. Maalouf NM, Cameron MA, Moe OW, et al. Low urine pH: A novel feature of the metabolic syndrome. 
Clin J Am Soc Nephrol 2007;2:883-888.

  34. Cameron M, Maalouf NM, Poindexter J, et al. The diurnal variation in urine acidification differs between normal individuals and uric acid stone formers. Kidney Int 2012;81:1123-1130.

  35. Rodman JS. Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 2002;60:378-382.